DUBLIN--(

都柏林--(

BUSINESS WIRE

商业热线

)--The

)--The

'Dry Eye Disease - Epidemiology Forecast - 2034'

'干眼症-流行病学预测-2034'

report has been added to

报告已添加到

ResearchAndMarkets.com's

ResearchAndMarkets.com的

offering.

提供。

The report delivers an in-depth understanding of Dry Eye Disease (DED), historical and forecasted epidemiology of Dry Eye Disease (DED) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

该报告深入了解了美国，EU4（德国，法国，意大利和西班牙）以及英国和日本的干眼病（DED），干眼病（DED）的历史和预测流行病学。

For the purpose of designing the patient-based model for the Dry Eye Disease (DED) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of DED, Gender-specific Diagnosed Prevalent Cases of DED, Age-specific Diagnosed Prevalent Cases of DED, and Severity-specific Diagnosed Prevalent Cases of DED in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034..

为了设计基于患者的干眼病（DED）流行病学模型，本报告中的章节提供了历史和预测流行病学，按2020年至2034年美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本的7MM范围内的DED总诊断流行病例、性别特异性诊断流行病例、年龄特异性诊断流行病例和严重程度特异性诊断流行病例进行细分。。

In the assessment done, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly 54.69 million in 2023. Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of DED with ~6,112 thousand cases, followed by Germany, which had diagnosed prevalent population of ~5,004 thousand in 2023.

在所做的评估中，2023年，估计在7MM中诊断出的DED流行病例总数接近5469万。在欧洲国家中，英国诊断出的DED流行病例最多，约为61.12万例，其次是德国，2023年诊断出的流行人口约为50.04万。

On the other hand, Spain had the lowest prevalent population (2,064 thousand cases)..

另一方面，西班牙的流行人口最低（2064000例）。。

The US reported the highest number of total diagnosed prevalent cases of DED among the 7MM countries with 41% whereas Japan reported the least cases (19%). This trend is anticipated to be followed during the forecast period as well. In the US, gender-specific diagnosed prevalent cases of DED revealed ~9,439 thousand cases among males and approximately ~13,035 thousand cases among females.

在700万个国家中，美国报告的DED确诊流行病例总数最高，为41%，而日本报告的病例最少（19%）。预计在预测期间也会遵循这一趋势。在美国，按性别诊断的DED流行病例显示，男性约94.39万例，女性约130.35万例。

Projections indicate that by 2034, the prevalence among females will surpass that of males..

预测表明，到2034年，女性患病率将超过男性。。

The analysis shows that the UK reported the highest number of DED cases in individuals aged 50 and older, with ~4,889 thousand cases. This was followed by ~691 thousand cases in the 40-49 age group and ~532 thousand cases in the 18-39 age group. Projections indicate that the UK is expected to continue leading in these figures by 2034..

分析表明，英国报告的50岁及以上人群中DED病例数量最多，约为48.89万例。其次是40-49岁年龄组约69.1万例，18-39岁年龄组约53.2万例。预测表明，到2034年，英国预计将继续在这些数字上领先。。

KOL Views

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

为了深入了解现实世界的流行病学见解，我们通过初步研究采纳了KOL和SME在该领域的意见，以填补数据空白并验证我们对疾病流行率的二次研究。

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Harvard Medical School, Boston, Massachusetts, US University of Pikeville, Kentucky College of Optometry, Pikeville, Kentucky, US; Magdeburg-Stendal University of Applied Sciences, Stendal, Sachsen-Anhalt, Germany; Department of Ophthalmology, Dijon University Hospital, Dijon, France; University of Milan, Milan, Italy; Optometry and Vision Science, Aston University, Birmingham, UK and Ryogoku Eye Clinic, Tokyo, Japan, and others were contacted.

分析师与20多名KOL联系，收集见解；然而，采访是在7MM内与10多名KOL进行的。美国马萨诸塞州波士顿哈佛医学院，美国皮克维尔大学，美国肯塔基州皮克维尔肯塔基验光学院等中心；马格德堡斯滕达尔应用科学大学，德国萨赫森·安哈尔特斯滕达尔；法国第戎第戎大学医院眼科；米兰大学，意大利米兰；联系了英国伯明翰阿斯顿大学的验光和视觉科学以及日本东京的Ryogoku眼科诊所等。

Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria..

他们的意见有助于了解和验证当前的疾病流行率、与疾病有关的性别、诊断率和诊断标准。。

Key Highlights

主要亮点

In 2023, the total diagnosed prevalence of Dry eye disease (DED) was highest in the US among the 7MM, accounting for nearly 22.47 million cases which is further expected to increase by 2034.

2023年，美国干眼病（DED）的总诊断患病率在700万人中最高，占近2247万例，预计到2034年将进一步增加。

In Japan, in 2023, ~2,341 thousand males and ~ 8.29 million females were affected with Dry eye disease (DED). estimates that these numbers might increase by 2034.

在日本，2023年，约有23.41万男性和约829万女性患有干眼症（DED）。估计到2034年这些数字可能会增加。

In 2023, the UK reported ~2,811 thousand mild, ~1,345 thousand moderate, and ~1,956 thousand severe cases of DED. Analysis by experts indicates that the overall severity-specific cases of DED are expected to rise in the coming years.

2023年，英国报告了约28.11万例轻度，约13.45万例中度和约195.6万例重度DED病例。。

The Dry Eye Disease (DED) cases are expanding due to increasing prevalence, rising awareness and better diagnostic capabilities, which increase demand for treatments. Advancements in research, increased funding for rare diseases, and the development of novel therapies are also key drivers.

由于患病率增加，意识提高和诊断能力提高，干眼症（DED）病例正在扩大，这增加了对治疗的需求。研究的进步，对罕见疾病的资金增加以及新疗法的开发也是关键驱动因素。

As per estimates, Japan accounted for nearly 19% of the Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM in 2023.

据估计，2023年，日本占7MM干眼病（DED）确诊流行病例总数的近19%。

Scope of the Report

报告的范围

The report covers a segment of key events, an executive summary, descriptive overview of Dry Eye Disease (DED), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

该报告涵盖了一部分关键事件，执行摘要，干眼症（DED）的描述性概述，解释其原因，体征和症状，以及目前可用的诊断算法和指南。

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

对流行病学部分和预测，诊断率的未来增长潜力，疾病进展和诊断指南提供了全面的见解。

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

该报告为了解趋势、专家见解/KOL视图和7MM内的患者旅程提供了优势。

A detailed review of current challenges in establishing the diagnosis.

详细回顾了目前在建立诊断方面面临的挑战。

Dry Eye Disease (DED) Report Insights

干眼症（DED）报告见解

Patient Population

患者人数

Country-wise Epidemiology Distribution

国家流行病学分布

Total Diagnosed Prevalent Cases of DED

诊断出的DED流行病例总数

Gender-specific Diagnosed Prevalent Cases of DED

性别特异性诊断的DED流行病例

Age-specific Diagnosed Prevalent Cases of DED

年龄特异性诊断的DED流行病例

Severity-specific Diagnosed Prevalent Cases of DED

严重程度特异性诊断的DED流行病例

Dry Eye Disease (DED) Report Key Strengths

干眼症（DED）报告的主要优势

11 years Forecast

11年预测

The 7MM Coverage

7MM的覆盖范围

Dry Eye Disease (DED) Epidemiology Segmentation

干眼病（DED）流行病学细分

Key Topics Covered:

涵盖的关键主题：

1. Key Insights

1、主要见解

2. Report Introduction

2、报告简介

3. Dry Eye Disease (DED) Epidemiology Overview at a Glance

3、干眼症流行病学概述

3.1. Patient Share Distribution of DED in 2020

三点一。2020年DED患者份额分布

3.2. Patient Share Distribution of DED in 2034

三点二。2034年DED患者份额分布

4. Epidemiology Methodology of DED

4.DED的流行病学方法

5. Executive Summary of Dry Eye Disease (DED)

干眼病（DED）执行摘要

6. Key Events

6、关键事件

7. Disease Background and Overview

7、疾病背景及概况

7.1. Introduction

7.1条。简介

7.2. Tear Film Working

七点二。

7.3. Etiology

七点三。病因

7.4. Risk Factors

七点四。风险因素

7.5. Pathophysiology

七点五。病理生理学

7.6. Symptoms and Clinical Presentations

七点六。症状和临床表现

7.7. Diagnosis

七点七。诊断

7.7.1. Diagnostic Criteria

7.7.1条。诊断标准

7.7.1.1. Comparison of Dry Eye Definition and Diagnostic Criteria between JDES/ADES and DEWS II

7.7.1.1。JDES/ADES和DEWS II干眼症定义和诊断标准的比较

7.7.1.2. Diagnostic Criteria of the JDES, 1995 Version

7.7.1.2。1995年版JDES诊断标准

7.7.1.3. Diagnostic criteria of DED proposed by the JDES (2006 version)

7.7.1.3。JDES（2006版）提出的DED诊断标准

7.7.2. Differential Diagnosis

7.7.2条。鉴别诊断

7.7.3. Diagnostic Algorithm

7.7.3。诊断算法

7.7.4. Diagnostic Scheme

7.7.4条。诊断方案

7.7.5. Diagnostic Guidelines

7.7.5条。诊断指南

7.7.5.1. Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology

7.7.5.1。美国眼科学会干眼综合征首选实践模式指南

8. Epidemiology and Patient Population

流行病学和患者人群

8.1. Key Findings

8.1条。

8.2. Assumptions and Rationale: The 7MM

。假设和理由：7MM

8.2.1. Diagnosed Prevalence of DED

8.2.1。诊断出的DED患病率

8.2.2. Gender-specific Prevalence of DED

8.2.2。DED的性别特异性患病率

8.2.3. Age-specific Diagnosed Prevalence of DED

8.2.3。DED的年龄特异性诊断患病率

8.2.4. Severity-specific Diagnosed Prevalence of DED

8.2.4。严重程度特定的DED诊断患病率

8.3. Total Diagnosed Prevalent Cases of DED in the 7MM

。7MM内确诊的DED流行病例总数

8.4. The United States

八点四。美国

8.5. EU4 and the UK

八点五。EU4和英国

8.5.1. Germany

8.5.1条。德国

8.5.2. France

8.5.2条。法国

8.5.3. Italy

8.5.3条。意大利

8.5.4. Spain

8.5.4条。西班牙

8.5.5. The United Kingdom

8.5.5节。英国

8.6. Japan

八点六。日本

9. Patient Journey

9、患者旅程

10. KOL Views

10. KOL Views

11. Appendix

11、附录

For more information about this report visit

有关此报告的更多信息，请访问

https://www.researchandmarkets.com/r/vegs1w

https://www.researchandmarkets.com/r/vegs1w

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。